Healthcare stayed in the red while the broader market rose, yet Immutep soared on a major deal, PolyNovo won an upgrade and EBOS emerged as Power’s pick to watch.
Rhythm Biosciences’ share price has jumped after announcing the start of commercialisation for ColoSTAT in Australia, its flagship blood-based colorectal cancer (CRC) test.
EBR Systems enrols their first patient and implant in the Totally Leadless CRT study for newly diagnosed heart failure patients at the Princess Alexandra Hospital, Brisbane.
